Blog
How to evaluate CTEM vendors: a buyer's checklist
By the time you are on a vendor call, “CTEM” has already been on the homepage for a year, and it tells you nothing about what the product does. Gartner’s exposure assessment platform category did not exist as a named market until its first Magic Quadrant in 2025, and the vendors who spent the prior decade selling vulnerability management moved into the new label within a quarter of each other. The label is marketing. The stage coverage is the product.
This is a checklist for the call, not a framework. Bring it to a demo and use it to make the vendor be specific.
Ask which stages, not whether it does CTEM
The only useful opening question is: which of the five stages does this product serve, natively, today, without a services engagement or a roadmap item. Scoping, discovery, prioritisation, validation, mobilisation. Get the answer stage by stage, because a vendor who answers “all five” in one sentence has not answered the question.
| Stage | Ask | Red flag answer |
|---|---|---|
| Scoping | How does the product help agree what’s in scope and its business criticality? | “You configure that yourself” with no criticality model at all |
| Discovery | Which sources does it collect natively versus ingest from something else? | Every source is a third-party integration |
| Prioritisation | Does ranking use attack path and reachability, or CVSS and asset count? | Severity score with a new coat of paint |
| Validation | Is exploitability proven by testing, or inferred from a feed? | “Our threat intelligence confirms exploitability” with no test run |
| Mobilisation | Does a fix get re-tested before the ticket closes, or does “closed” mean the ticket status changed? | No re-test step exists |
Demand a live example for each answer, not a slide. A vendor who can show the actual screen where a validated exposure becomes a ticket with an owner and a re-test date has a product. A vendor who describes the workflow in the future tense has a roadmap.
The rebrand red flag
The single most common failure mode in this market is a vulnerability scanner that renamed its dashboard “exposure management” and added a fifth column to the report labelled “validation,” where validation means the vendor’s own threat feed says an exploit exists somewhere in the world. That is not stage four. Stage four means the tool, or a person using the tool, actually attempted the exploit, safely, in the buyer’s environment, and recorded whether it worked and whether anything detected it.
Ask directly: when your platform marks something “validated,” what happened? If the answer involves the words “threat intelligence,” “confirmed available,” or “known exploited,” without the words “ran,” “attempted,” or “tested,” it is inference, not proof. Gartner’s Market Guide for Adversarial Exposure Validation makes this exact distinction (Gartner, March 2025), and its own estimate of how few organisations will have formal validation by 2027 means most vendor pitches today are describing a future the market has not reached. The metrics post has the number.
A second version of the same red flag shows up in mobilisation. Ask whether “remediated” in the reporting means a ticket was closed or a fix was re-tested. Verizon’s 2025 Data Breach Investigations Report found that a large share of the known-exploited edge-device vulnerabilities it tracked were never fully remediated at all, and the ones that were took weeks (the metrics post has the numbers and the source). A platform that reports on ticket status rather than verified closure will always look better than the DBIR figures, and for the wrong reason.
Integration and API access
Ask for the API documentation before the call, not after the contract is signed. Two things matter: whether findings can be pulled out in a structured format without a professional services request, and whether the product can ingest findings from the tools already in place rather than only from its own sensors.
Ask specifically which of the connectors advertised on the website are generally available versus in preview, and whether non-native connectors move to a different pricing tier later. More than one exposure platform in this market ships its richest integrations as preview features that become metered add-ons once out of preview. That is a pricing question disguised as a technical one, so ask it as both.
Proof-of-value pilots
Insist on a pilot against the buyer’s own environment, not a demo environment or a synthetic range. Thirty days is enough. Scope the pilot to a slice narrow enough that the vendor cannot hide behind coverage gaps: one business unit’s external surface, or one cloud account.
Set the success criteria before the pilot starts, in writing, and make them about outcomes rather than counts. Not “how many findings,” but “how many findings were validated exploitable, how long did a fix take from validation to re-tested closure, and how many false positives did the team spend time chasing.” A vendor confident in the product will agree to this. A vendor who pushes back on defined success criteria is telling something.
Pricing models
Get the pricing unit before the demo ends: per asset, per user, per finding volume, or a flat enterprise quote. Most of this market prices on an enterprise quote with no public number, which is a legitimate business choice, but it also means the number will not be comparable across vendors without doing the arithmetic on the buyer’s own asset count first.
Ask what happens to the price when asset count grows, when a preview integration becomes generally available, and when a validation module that was bundled in the pilot moves to its own line item. Exposure platforms in particular tend to unbundle validation, attack path analysis and mobilisation orchestration into separate SKUs once the pilot ends. Get that unbundling in writing before signing, not after the first renewal.
Avoiding five tools that don’t talk
The market is shaped so that no single category covers all five stages well, which is documented in the tools guide. The buying mistake that follows from that fact is assembling five best-of-breed point tools, one per stage, and discovering a year later that none of them share a data model, an asset identifier, or a workflow. Each tool produces its own dashboard, and mobilisation becomes a person copying findings between systems by hand.
Pick a spine deliberately. Either an exposure platform that owns discovery, prioritisation and mobilisation, paired with one validation specialist that feeds it evidence, or an aggregation layer whose entire job is normalising and deduplicating findings from everything else. Ask any prospective vendor which role they expect to play in a multi-tool stack, because a vendor who insists it is the only tool needed, when the directory shows no single product covers all five stages well, is not being straight about the market it sells into.
Next
The vendor directory records stage-by-stage coverage for the products named here, reviewed and dated. The tools guide explains what each category of tool is actually for before a call starts. The assessment is a faster way to know which stage is weakest before deciding what to buy for it.